38 related articles for article (PubMed ID: 26358784)
1. Prediction of Promiscuity Cliffs Using Machine Learning.
Blaschke T; Feldmann C; Bajorath J
Mol Inform; 2021 Jan; 40(1):e2000196. PubMed ID: 32881355
[TBL] [Abstract][Full Text] [Related]
2. Systematic identification of target set-dependent activity cliffs.
Hu H; Stumpfe D; Bajorath J
Future Sci OA; 2019 Feb; 5(2):FSO363. PubMed ID: 30828462
[TBL] [Abstract][Full Text] [Related]
3. Anatomy of Potency Predictions Focusing on Structural Analogues with Increasing Potency Differences Including Activity Cliffs.
Janela T; Bajorath J
J Chem Inf Model; 2023 Nov; 63(22):7032-7044. PubMed ID: 37943257
[TBL] [Abstract][Full Text] [Related]
4. Data structures for compound promiscuity analysis: promiscuity cliffs, pathways and promiscuity hubs formed by inhibitors of the human kinome.
Miljković F; Bajorath J
Future Sci OA; 2019 Jul; 5(7):FSO404. PubMed ID: 31428450
[TBL] [Abstract][Full Text] [Related]
5. Increasing the public activity cliff knowledge base with new categories of activity cliffs.
Hu H; Bajorath J
Future Sci OA; 2020 Apr; 6(5):FSO472. PubMed ID: 32518687
[TBL] [Abstract][Full Text] [Related]
6. Correction to "Exposing the Limitations of Molecular Machine Learning with Activity Cliffs".
van Tilborg D; Alenicheva A; Grisoni F
J Chem Inf Model; 2023 Oct; ():. PubMed ID: 37851546
[No Abstract] [Full Text] [Related]
7. Cliffs as priority ecosystems.
March-Salas M; Lorite J; Bossdorf O; Scheepens JF
Conserv Biol; 2023 Oct; 37(5):e14166. PubMed ID: 37551743
[No Abstract] [Full Text] [Related]
8. High Impact: The Role of Promiscuous Binding Sites in Polypharmacology.
Cerisier N; Petitjean M; Regad L; Bayard Q; Réau M; Badel A; Camproux AC
Molecules; 2019 Jul; 24(14):. PubMed ID: 31295958
[TBL] [Abstract][Full Text] [Related]
9. Predicting Subtype Selectivity for Adenosine Receptor Ligands with Three-Dimensional Biologically Relevant Spectrum (BRS-3D).
He SB; Ben Hu ; Kuang ZK; Wang D; Kong DX
Sci Rep; 2016 Nov; 6():36595. PubMed ID: 27812030
[TBL] [Abstract][Full Text] [Related]
10. Activity cliff networks for medicinal chemistry.
Stumpfe D; Bajorath J
Drug Dev Res; 2014 Aug; 75(5):291-8. PubMed ID: 25160069
[TBL] [Abstract][Full Text] [Related]
11. Scanning structure-activity relationships with structure-activity similarity and related maps: from consensus activity cliffs to selectivity switches.
Medina-Franco JL
J Chem Inf Model; 2012 Oct; 52(10):2485-93. PubMed ID: 22989212
[TBL] [Abstract][Full Text] [Related]
12. Systematic Assessment of Molecular Selectivity at the Level of Targets, Bioactive Compounds, and Structural Analogues.
Hu Y; Bajorath J
ChemMedChem; 2016 Jun; 11(12):1362-70. PubMed ID: 26358784
[TBL] [Abstract][Full Text] [Related]
13. From structure-activity to structure-selectivity relationships: quantitative assessment, selectivity cliffs, and key compounds.
Peltason L; Hu Y; Bajorath J
ChemMedChem; 2009 Nov; 4(11):1864-73. PubMed ID: 19750525
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of single- and multi-target activity cliffs formed by currently available bioactive compounds.
Wassermann AM; Dimova D; Bajorath J
Chem Biol Drug Des; 2011 Aug; 78(2):224-8. PubMed ID: 21624090
[TBL] [Abstract][Full Text] [Related]
15. Activity profile relationships between structurally similar promiscuous compounds.
Hu Y; Bajorath J
Eur J Med Chem; 2013 Nov; 69():393-8. PubMed ID: 24077530
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
